摘要
目的探索表皮生长因子受体(EGFR)低表达、环氧合酶-2(COX-2)高表达和微血管密度(MVD)高表达的分期为T1N0M0的非小细胞肺癌(NSCLC)是否需要接受术后辅助化疗。方法通过非随机对照临床研究的方法,收集早期NSCLC(分期为T1N0M0),并经过免疫组化证实为EGFR低表达、COX-2高表达和MVD高表达的患者为试验组,接受顺铂(DDP)联合诺维本(NVB)化疗;对照组为既往分期相同且免疫组化状态相同的早期NSCLC患者,术后没有接受任何抗肿瘤治疗。结果试验组10例,对照组13例。试验组的中位无病生存期为40个月,而对照组为25个月,但差异无显著性(P=0.079)。结论高危的早期NSCLC(分期为T1N0M0)患者接受化疗后有望取得更好的生存获益,有必要开展大规模的随机对照研究去证实。
Objective To study the necessity of adjuvant chemotherapy in early-stage non-small cell lung cancer（NSCLC）with overexpression of cyclooxygenase-2（COX-2）and microvessel density（MVD） and low expression of epidermal growth factor receptor（EGFR）.Methods A non-randomized controlled study was performed.The patients with early-stage NSCLC（T1N0M0） with overexpression of COX-2 and MVD and low expression of EGFR were enrolled into this study.The treatment group accepted adjuvant chemotherapy with cisplatin plus navelbine after operation.The control group（observation group）did not receive any antitumor therapy after operation.Results Ten patients were treated with adjuvant chemotherapy,13 patients did not receive adjuvant chemotherapy.The median disease-free survival of patients treated with adjuvant chemotherapy was 40 months compared with 25 months in patients of control group,but there was no significant difference between these two arms（P=0.079）.Conclusion Results of this trial suggest that high risk early-stage NSCLC（T1N0M0） with overexpression of COX-2 and MVD without a concomitant overexpression of EGFR may need adjuvant chemotherapy,which warrants further studies.
出处
《中国肿瘤临床与康复》
2011年第1期31-32,35,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
基金
中山市医学科学技术研究基金立项(2005C029)
关键词
肺肿瘤
表皮生长因子受体
环氧合酶-2
微血管密度
Lung neoplasms
Epidermal growth factor receptor
Cyclooxygenase-2
Microvessel density
